San Francisco, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Global Home Infusion Therapy Market is expected to reach USD 31.9 billion by 2022. Rising incidence of chronic disorders has led to an augmentation in the demand for infusion therapy in outpatient settings, thereby boosting the home infusion therapy market. Rapidly growing geriatric population base globally, is also likely to serve this market as a high impact rendering driver. The home infusion therapy is considered beneficial for patients as they get the entire treatment at the comfort of their home. Furthermore, home infusion therapy is a cost effective alternative to placement in hospital, and allows patients to adhere to their normal lifestyle while receiving treatment. Rising incidences of hospital acquired infections is a high impact rendering driver of this market. Additional healthcare spending associated with these infections are expected to encourage patients to prefer home care over the conventional settings.
Browse Full Research Report With TOC On "Home Infusion Therapy Market Size, Report, 2022" at: http://www.radiantinsights.com/research/home-infusion-therapy-market-analysis-by-product-infusion-pumps-intravenous-sets-iv-cannulas-needleless-connectors-by-application-anti-infective-hydration-therapy-chemotherapy-enteral-nutrition-parenteral-nutrition-specialty-pharmaceuticals-and-segment-forecasts-to-2022
Further key findings from the study suggest:
- Needleless connectors are expected to witness lucrative growth over the forecast period. Growing demand for enhanced healthcare service provider safety has led to the rise in demand for needleless connectors.
- Anti-Infective dominated the market with a revenue share of over 25.0% in 2014. Home administration of anti-infective therapy is preferred by patients who have chronic infections that cannot be treated through oral agents. It is considered as the most user friendly home infusion therapy.
- North America accounted for more than 40% of the home infusion therapy market in 2014 on account of the presence of large geriatric population base. Presence of sophisticated healthcare infrastructure and favorable reimbursement plans laid out by regulatory bodies are also expected to make significant contributions towards market growth.
- Asia Pacific is expected to emerge as a high growth market over the forecast period. Presence of large unmet needs in the emerging economies such as China and India. Rising patient awareness levels regarding the benefits of home infusion therapies over the in-hospital infusion therapies is expected to further boost the growth of this region.
- Key players of home infusion therapy market include B. Braun Melsungen AG, Fresenius Kabi AG, Baxter, CareFusion Corporation and Hospira Inc. Mergers and acquisitions and entering into strategic collaborations with healthcare providers are two key sustainability strategies adopted by these market participants.
Browse All Reports of This Category at: http://www.radiantinsights.com/catalog/medical-devices
Global Home Infusion Therapy Product Outlook (Revenue, USD Million, 2012 - 2022)
- Infusion pumps
- Intravenous Sets
- IV Cannulas
- Needleless Connectors
Global Home Infusion Therapy Application Outlook (Revenue, USD Million, 2012 - 2022)
- Anti-Infective
- Hydration Therapy
- Chemotherapy
- Enteral Nutrition
- Parenteral Nutrition
- Specialty Pharmaceutical
- Others
Home Infusion Therapy Regional Outlook (Revenue, USD Million, 2012 - 2022)
- North America
- S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- Japan
- China
- Latin America
- Brazil
- Middle East and Africa (MEA)
- South Africa
Related Reports by Radiant Insights:
- Global Printed Batteries Market –
http://www.radiantinsights.com/research/global-printed-batteries-market-2014-2018
- Global Software Testing System Integrator Market –
http://www.radiantinsights.com/research/global-software-testing-system-integrator-market-2014-2018
About Radiant Insights
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy.Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: [email protected]
Web: http://www.radiantinsights.com/


Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking.
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 



